Monoclonal Antibody Infliximab Biosimilar from Canada
A biotechnologically produced chimeric monoclonal antibody targeting TNF-alpha, used to treat inflammatory conditions like Crohn's disease. It qualifies under HTS 3002.12.0090 as an immunological product (per chapter note) obtained via biotech processes from blood fraction-inspired cell cultures. This covers modified proteins regulating immune processes.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Except as provided in heading 9903.04.61, patented pharmaceutical articles as provided for in subdivisions (c) and (d) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
Import Tips
• Submit IND or BLA documentation proving therapeutic immunological function to justify Chapter 30 classification
• Monitor for biotech origin certification; declare purity levels >95% to avoid Chapter 35 peptide reclassification